logo
$1M from Co-operators Powers Kids Help Phone Peer-to-Peer Community for Youth Across Canada

$1M from Co-operators Powers Kids Help Phone Peer-to-Peer Community for Youth Across Canada

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) —
Kids Help Phone (KHP)
is proud to announce that with a renewed commitment
Co-operators
has reached $1M in support of youth through KHP's Feel Out Loud movement — Canada's largest movement for youth mental health. This latest contribution will help expand access to essential support and services for young people across the country.
This commitment builds on Co-operators legacy of supporting youth mental health for more than three decades. As a founding donor of KHP's 24/7 texting service and the Peer-to-Peer Community, Co-operators has been instrumental in driving forward some of KHP's most impactful mental health innovations.
This transformative investment will support the Peer-to-Peer Community, empowering youth from coast-to-coast-coast with a safe, co-created, youth-led online space to explore and let their feelings out. KHP staff and Peer-to-Peer moderators will also explore innovative approaches to maximize the impact of the platform, ensuring even more young people across Canada feel safe, supported, and heard as they engage with the Peer-to-Peer Community.
In 2024, the Peer-to-Peer Community platform had a record 301,693 interactions, marking a 15% increase in volume compared to 2023, and the highest number of interactions since its launch in 2021.
As a core component of KHP's vision for a more personalized and equitable e-mental health ecosystem, the Peer-to-Peer Community helps ensure youth can access the support they deserve in the ways that work best for them.
'Co-operators latest investment in KHP's services is a powerful example of the lasting impact that comes from a strong, long-term partnership,' said Susan Morris, Interim President & Co-CEO, KHP. 'Their ongoing generosity has helped us create safe, inclusive spaces where young people can turn to one another for connection and hope. We are incredibly grateful for their unwavering commitment to youth mental health.'
'Young people deserve mental health support that's accessible, inclusive, and designed with them in mind,' said Shawna Peddle, Associate Vice-President, Citizenship at Co-operators. 'We're honoured to support KHP's Feel Out Loud movement and the Peer-to-Peer Community, ensuring more young people have safe spaces to feel heard, supported, and empowered to navigate life's challenges.'
Together, KHP and Co-operators are building a more supportive, connected future where all young people in Canada have the opportunity to grow stronger, together.
FAST FACTS
About Kids Help Phone
Kids Help Phone (KHP) is Canada's only 24/7, free, confidential, and multilingual e-mental health solution. Whether through professional counselling, crisis response, or self-directed mental health resources, KHP has been a trusted space for youth for over 35 years. No matter the feeling or issue, big or small, KHP empowers young people to Feel Out Loud and access support whenever they need it most. KHP knows that young people and the issues they are facing are changing faster than ever. That's why innovation is more than what we do – it's who we are: a global leader in youth mental health that blends technology with empathy to better serve youth. KHP gratefully relies on the generosity of donors, volunteers, stakeholder partners, corporate partners and governments to unlock the hope young people need to thrive in their worlds. Join us at
kidshelpphone.ca
.
About Co-operators
Proudly Canadian since 1945, Cooperators is a leading financial services co-operative, offering multi-line insurance and investment products, services, and personalized advice to help Canadians build their financial strength and security. With more than $72 billion in assets under administration, Cooperators is well known for its community involvement and its commitment to sustainability. Currently a carbon neutral organization, Co-operators is committed to net-zero emissions in its operations and investments by 2040, and 2050, respectively. Cooperators is recognized as one of Canada's Top 100 Employers and ranked as one of Corporate Knights' Best 50 Corporate Citizens in Canada. For more information, please visit:
www.cooperators.ca
.
For media inquiries:
Email:
media@cooperators.ca
For more information, please contact:
Kids Phone Communications Team
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Analysts Are Bullish on Top Technology Stocks: Sunny Optical Technology (Group) Co (SNPTF), Lam Research (LRCX)
Analysts Are Bullish on Top Technology Stocks: Sunny Optical Technology (Group) Co (SNPTF), Lam Research (LRCX)

Business Insider

timea day ago

  • Business Insider

Analysts Are Bullish on Top Technology Stocks: Sunny Optical Technology (Group) Co (SNPTF), Lam Research (LRCX)

There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Sunny Optical Technology (Group) Co (SNPTF – Research Report) and Lam Research (LRCX – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Sunny Optical Technology (Group) Co (SNPTF) DBS analyst Jim Hin Kwong Au maintained a Buy rating on Sunny Optical Technology (Group) Co today and set a price target of HK$110.00. The company's shares closed last Tuesday at $9.87. According to Au is a 5-star analyst with an average return of 18.4% and a 69.7% success rate. Au covers the Technology sector, focusing on stocks such as BYD Electronic (International) Co, AAC Technologies Holdings, and ASM Pacific Technology. Currently, the analyst consensus on Sunny Optical Technology (Group) Co is a Strong Buy with an average price target of $12.17. Lam Research (LRCX) In a report released yesterday, Vijay Rakesh from Mizuho Securities reiterated a Buy rating on Lam Research, with a price target of $120.00. The company's shares closed last Tuesday at $100.33. According to Rakesh is a 5-star analyst with an average return of 21.5% and a 59.8% success rate. Rakesh covers the Technology sector, focusing on stocks such as Credo Technology Group Holding Ltd, Advanced Micro Devices, and ARM Holdings PLC ADR. Currently, the analyst consensus on Lam Research is a Strong Buy with an average price target of $112.64, a 14.0% upside from current levels. In a report issued on August 14, Erste Group also initiated coverage with a Buy rating on the stock.

Eli Lilly (LLY) Sells Record $6.75 Billion of Corporate Bonds
Eli Lilly (LLY) Sells Record $6.75 Billion of Corporate Bonds

Business Insider

timea day ago

  • Business Insider

Eli Lilly (LLY) Sells Record $6.75 Billion of Corporate Bonds

Pharmaceutical company Eli Lilly & Co. (LLY) has priced its biggest-ever sale of U.S. investment-grade corporate bonds. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The debt issuance includes a 40-year bond, which is extremely rare among U.S. corporations today given elevated interest rates and high borrowing costs. The Indiana-based drug maker sold a total of $6.75 billion worth of debt in seven parts, with the 40-year tranche yielding 0.73 percentage points above current U.S. Treasuries. The deal also includes a 30-year portion, as well as maturities ranging from three to 10 years, according to the company. Eli Lilly plans to use proceeds from the bond sale for general corporate purposes, which may include paying down some of the company's debt, which currently stands at about $35 billion. Long-Dated Bonds Eli Lilly's latest bond offering comes amid a limited supply of long-dated corporate bonds. Just 11% of high-grade debt sold this year had a maturity of 30 years or more, down from 15% in 2024, as companies are increasingly hesitant to lock in elevated borrowing costs for long periods of time in the current market. Eli Lilly was one of several well-known American companies to tap the bond market on Aug. 18. Other borrowers included McDonald's (MCD), Marriott International (MAR), and Charter Communications (CHTR). Companies in the U.S. are issuing debt now ahead of a seasonal slowdown in early September, and with spreads at their lowest level since 1998. Is LLY Stock a Buy? The stock of Eli Lilly has a consensus Strong Buy rating among 22 Wall Street analysts. That rating is based on 17 Buy and five Hold recommendations issued in the last three months. The average LLY price target of $924.42 implies 30.22% upside from current levels.

Stock Option Traders Smell Blood in the Water After Eli Lilly's (LLY) Q2 Fumble
Stock Option Traders Smell Blood in the Water After Eli Lilly's (LLY) Q2 Fumble

Business Insider

timea day ago

  • Business Insider

Stock Option Traders Smell Blood in the Water After Eli Lilly's (LLY) Q2 Fumble

One of the harsh realities of the equities arena is that it's open and entropic. In other words, exogenous factors could come in and disrupt the paradigm — seemingly without warning. That was pretty much the case with pharmaceutical giant Eli Lilly & Co. (LLY) earlier this month. Despite strong results for the second quarter, LLY stock tumbled badly after the disclosure. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. At first glance, the red ink would appear to be an overreaction, perhaps a sick joke. Earnings per share landed at $6.31, well above Wall Street analysts' consensus view of $6.07. In the year-ago quarter, the pharma posted EPS of $3.92. On the top line, Eli Lilly generated $15.56 billion, up 5.83% over the consensus estimate of $15.42 billion. One year ago, the company reported revenue of $11.3 billion. According to David Ricks, Eli Lilly Chairman and CEO, 'Lilly delivered another quarter of strong performance, achieving 38% year-over-year revenue growth driven by robust sales of Zepbound and Mounjaro and sustained momentum across our key medicines.' So, what was the problem? The pharma released clinical trial data for weight-loss pill orforglipron, which met its primary endpoint but with results that didn't quite match expectations. Still, from a fundamental perspective, it's hard to argue against LLY stock. With management raising its 2025 guidance, the enterprise appears to be brimming with confidence. However, for stock options traders, a currently active quantitative signal suggests a bullish upturn in LLY stock is just around the corner. Applying the Proper Epistemological Framework for LLY Stock While participating in the derivatives market opens the door to leveraged positions, it comes with a vast set of risks. In many cases, options represent all-or-nothing wagers: either the strategy will be in the money or it will not. Further, the probabilistic window is tightened because eventually, all options expire. Therefore, you can't ride out volatility indefinitely like you can with open-market transactions. Given the unique risk profiles associated with options trading, it's vital to maintain statistical continuity between input and output variables in your stock forecasting model. In traditional financial analyses — whether the fundamental or technical approach — this continuity is broken. Commonly studied metrics (such as earnings or share price) are continuous scalar signals, meaning that they're unbounded. However, from these signals, analysts extract discrete meaning, such as 'good price' or 'bad earnings.' Essentially, many market analysts are unintentionally committing a category error, using one domain of reality to predict outcomes in an entirely different domain. To avoid this statistical flaw, I propose instead to maintain framework consistency by recognizing the only objective truth in the equities sector: at the end of any trading session, the market is either a net buyer or a net seller. Put simply, I'm no longer concerned with the ordinary ebb and flow. What I want instead is to uncover the market's voting record—operating on the premise that the aggregate of buying and selling decisions carries predictive value for where the target security may move next. Mathematically, my forecasting model is descriptive: I take what has conditionally happened in the past and project what could happen in the future. This approach is conceptually different from the standard approach of options trading, which involves derivations from the Black-Scholes formula to estimate where the stock in question may end up. This is a prescriptive approach because it focuses on where a stock should trade. However, I firmly believe that descriptive path dependency is superior because the estimates stem from actual behavioral geometry — not advanced math that is aesthetically pleasing but functionally useless. Converting Theory Into Application In the equities arena, converting continuous scalar signals into discrete objects is easy: just compress the price action into net accumulative or distributive sessions. In the case of LLY stock, in the past 10 weeks, the market voted to buy LLY six times and sell four times. During this period, the security incurred a downward trajectory. For brevity, we can label this sequence as 6-4-D. It's an odd pattern as the balance of accumulative sessions outweighs distributive, yet the trajectory is negative. Historically, though, the sequence has resulted in a sentiment reversal more often than not. In fact, in 68.42% of cases (going back to January 2019), the price action of LLY stock rises, with a median return of 2.47%. What makes Eli Lilly compelling for bullish options traders is that, as a baseline, the chance that a long position in LLY stock will rise on any given week is 60.12%. Essentially, this is the null hypothesis or the probabilistic performance expectation assuming no mispricing. Any options strategy must be able to beat the null on paper; otherwise, there's no point. Clearly, with a 68.42% probabilistic edge, the 6-4-D sequence offers an incentive for bullish speculators to take a risk. Moreover, based on past analogs, there's a solid possibility that LLY stock could exceed the $750 level by the September 19th expiration date. With that said, I'm tempted by the 720/730 bull call spread expiring September 19th. This transaction involves buying the $720 call and simultaneously selling the $730 call, for a net debit paid of $400 (the maximum possible loss). Should LLY stock rise through the short strike price of $730 at expiration, the maximum profit is $600, a payout of 150%. Is Eli Lilly a Buy, Sell, or Hold? Turning to Wall Street, LLY stock carries a Strong Buy consensus rating based on 17 Buys, five Holds, and zero Sell ratings over the past three months. LLY's average stock price target is $924.42, implying ~32% upside potential over the coming year. LLY Can Turn the Ship Around While the recent volatility in LLY stock hasn't been helpful for longtime stakeholders, the red ink opens the door for new speculators to enjoy a potential discount. Based on a statistical analysis of prior like-to-like conditions, LLY is potentially on course to hit $750 over the next five weeks. Right now, there's a compelling bull call spread that offers a huge payout at the $730 mark — making it a deal well worth considering.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store